138998-46-6

Basic information

• Product Name: ethyl 3-(dimethylamino)-2-(2,4,5-trifluorobenzoyl)prop-2-enoate
• Synonyms: ethyl 3-(dimethylamino)-2-(2,4,5-trifluorobenzoyl)prop-2-enoate
• CAS NO: 138998-46-6
• Molecular Weight: 301.265
• Mol File: 138998-46-6.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: ethyl 3-(dimethylamino)-2-(2,4,5-trifluorobenzoyl)prop-2-enoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 3-(dimethylamino)-2-(2,4,5-trifluorobenzoyl)prop-2-enoate(138998-46-6)
• EPA Substance Registry System: ethyl 3-(dimethylamino)-2-(2,4,5-trifluorobenzoyl)prop-2-enoate(138998-46-6)

Safety Data

• Hazardous Substances Data: 138998-46-6(Hazardous Substances Data)

Upstream product

• 129322-83-4 2',4',5'-trifluoroacetophenone 
• 98349-24-7 ethyl 2,4,5-trifluorobenzoylacetate 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 446-17-3 2,4,5-trifluorobenzoic acid 
• 924-99-2 ethyl 3-(dimethylamino)acrylate 
• 88419-56-1 2,4,5-trifluorobenzoyl chloride 

Downstream Products

• 98349-25-8 ethyl 1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylate 
• 85721-33-1 ciprofloxacin 
• 1429439-96-2 4-methoxybenzyl 1-cyclopropyl-6,7-bis((4-methoxybenzyl)oxy)-4-oxo-1,4-dihydroquinolin-3-carboxylate 
• 101799-76-2 3-Cyclopropylamino-2-(2,4,5-trifluorbenzoyl)acrylsaeure-ethylester 
• 93107-08-5 ciprofloxacin hydrochloride 
• 105404-65-7 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate ethyl ester 
• 1429440-05-0 5-chloro-1-cyclopropyl-6,7-bis((4-methoxybenzyl)oxy)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1429440-04-9 4-methoxybenzyl 5-chloro-1-cyclopropyl-6,7-bis((4-methoxybenzyl)oxy)-4-oxo-1,4-dihydroquinolin-3-carboxylate 
• 1429439-97-3 1-cyclopropyl-6,7-bis((4-methoxybenzyl)oxy)-4-oxo-1,4-dihydroquinolin-3-carboxylic acid 
• 1429439-92-8 1-(tert-butyl)-6,7-bis((4-methoxybenzyl)oxy)-4-oxo-1,4-dihydroquinolin-3-carboxylic acid 

Relevant articles and documents

FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING)

The present invention relates to compound-linker constructs and antibody-drug-conjugates of compounds of formula (I) that are useful as modulators of STING (Stimulator of Interferon Genes).

On-Demand Continuous Manufacturing of Ciprofloxacin in Portable Plug-and-Play Factories: Development of a Highly Efficient Synthesis for Ciprofloxacin

The experimental approach taken and challenges overcome in developing a high-purity production (>100 g) scale process for the telescoped synthesis of the antibiotic ciprofloxacin is outlined. The process was first optimized for each step sequentially with regard to purity and yield, with necessary process changes identified and implemented before scaling for longer runs. These changes included implementing a continuous liquid-liquid extraction (CLLE) step and eliminating and replacing the base 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) initially used in the ring-closure step due to DBU plausibly forming a decomposition side product that negatively impacted the final product purity. Process conditions were scaled 1.5-2-fold in order to enable the ultimate project goal of producing enough crude ciprofloxacin within 24 h to manufacture 1000 250 mg tablets. Working toward this goal, several production-scale runs were carried out to assess the reproducibility and robustness of the finalized process conditions, with the first three steps being run continuously up to 22 h and the last two steps being run continuously up to 10 h. The end result is a process with a throughput of ～29 g/h (～700 g/24 h) with a crude product stream profile of 94 ± 2% and 34 ± 3 mg/mL after five chemical transformations across four reactors and one continuous CLLE unit operation with each intermediate step maintaining a purity >95% by HPLC.

2 - Substituted cephem compound-containing pharmaceutical composition

PROBLEM TO BE SOLVED: To provide a cephem compound which has a strong antimicrobial activity, in particular effective against various β-lactamase producing Gram negative bacteria, and a composition comprising the compound.SOLUTION: The present invention provides a pharmaceutical composition comprising a compound represented by formula (I), an ester at a carboxyl group, an amino-protected compound when the amino is present on a ring in the 7-side chain, or a pharmaceutically acceptable salt thereof.